Abstract
Kinin is an important mediator of hyperalgesia, inflammatory conditions and asthma. It causes pain, inflammation, increased vascular permeability and vasodilatation. Several kinin antagonists have been developed with the aim of treating these pathologies. Kinin B2 receptor agonists and kallikrein may have clinical utility in the treatment of hypertension, left ventricular hypertrophy, ischemic heart disease, congestive heart failure and diabetes. However, there is a need to know whether there is a safe therapeutic window between potential cardio-protective and pro-inflammatory effects following administration of kinin B2 receptor agonists.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Chao, J. and Chao, L. (1998). Kallikrein gene therapy in hypertension, cardiovascular and renal diseases, Gen. Ther. Mol. Biol. 1, 301–308.
Bathon, J. M., Manning, D. C., Goldman, D. W., et al. (1992). Characterization of kinin receptors on human synovial cells and upregulation of receptor numbers by interleukin-1, J. Pharmacol. Exp. Ther. 260, 384–392.
Burch, R. M. and DeHaas, C. (1990). A bradykinin antagonist inhibits carrageenan edema in rats, Naunyn-Schmiedeberg’s Arch. Pharmacol. 342, 189–193.
Di Rosa, M., Giroud, J. P. and Willoughby, D. A. (1971). Studies of the mediators of acute inflammatory response induced in rats in different sites by carrageenana and turpentine, J. Pathol. 104, 15–29.
Kichuck, M. R., Seyedi, N., Zhang, X., et al. (1996). Regulation of nitric oxide production in human coronary microvessels and the contribution of local kinin formation, Circulation 94, 44–51.
Koide, A., Zeitlin, I. J. and Parratt, J. R. (1993). Kinin formation in ischemic heart and aorta of anaesthetized rats, J. Physiol. 467, 125P.
Linz, W., Wiemer, G. and Scholkens, B. A. (1993). Bradykinin prevents left ventricular hypertrophy in rats, J. Hypertens. 11(Suppl. 5), S96–S97.
Ljunggren, O. and Lerner, U. H. (1990). Evidence for Bk1 bradykinin receptor-mediated prostaglandin formation in osteoblasts and subsequent enhancement of bone resorption, Br. J. Pharmacol. 101, 382–386.
Locherner, W. and Parratt, J. R. (1966). A comparison of the effects of locally and systematically administration of kinin on coronary blood flow and myocardial metabolism, Br. J. Pharmacol. Chemother. 26, 17–26.
Morgolius, H. S., Geller, A., de Jong, W., et al. (1972). Altered urinary kallikrein excretion in rats hypertension, Circ. Res. 30, 358–362.
Sharma, J. N. (1991). The role of kallikrein-kinin system in joint inflammatory disease, Eur. J. Rheumatol. Inflamm. 11, 30–36.
Sharma, J. N. (2003). Does the kininn system mediate in cardiovascular abnormalities? An overview, J. Clin. Pharmacol. 43, 1187–1195.
Sharma, J. N. and Buchanan, W. W. (1994). Pathogenic responses of bradykinin system in chronic inflammatory rheumatoid disease, Exp. Toxicol. Pathol. 46, 421–433.
Sharma, J. N. and Wirth, K. J. (1996). Inhibition of rats adjuvant arthritis by a bradykinin antagonist Hoe 140 and its influence on kallikrein, Gen. Pharmacol. 27, 133–136.
Sharma, J. N., Amrah, S. S. and Noor, A. R. (1995). Suppression of hypotensive responses of captopril and enalapril by kallikrein inhibitor aprotinin in spontaneously hypertensive rats, Pharmacology 50, 363–369.
Sharma, J. N., Yusof, A. P. M. and Wirth, K. J. (1998). The kinin antagonist Hoe 140 reduces acute paw oedema in rats caused by carrageenan, bradykinin and kaolin, Inflammopharmacology 6, 9–17.
Sharma, J. N., Zubaid, M., Khan, B. Z. S. J., et al. (2000). Pathphysiological activities of the kallikrein-kinin system with emphasis on the cardiovascular disorders, Inflammopharmacology 8, 219–241.
Sharma, J. N. and Sharma, J. (2002). Cardiovascular properties of the kallikrein-kinin system, Curr. Med. Res. Opin. 18, 10–17.
Sharma, J. N., Uma, K. and Yusof, A. P. M. (1998). Left ventricular hypertrophy and its relation to cardiac kinin-forming system in hypertensive and diabetic rats, Int. J. Cardiol. 63, 229–235.
Sharma, J. N., Abbas, S. A., Yusof, A. P. M., et al. (2003). Evaluation of tissue kallikrein activity on survival time after acute coronary artery ligation in hypertensive rats, Int. Immunopharmacol. 3, 329–334.
Sharma, J. N., Abbas, S. A., Yusof, A. P. M., et al. (2004). Tissue kallikrein increases survival after prolonged coronary artery ligation in hypertensive rats, Pharmacology 70, 201–205.
Zhu, P., Zugga, C. E., Simper, D., et al. (1995). Bradykinin improves post-ischaemic recovery in that rat heart: role of high energy phosphate, nitric oxide and prostacyclin, Cardiovasc. Res. 29, 658–663.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sharma, J.N. The kallikrein-kinin system: from mediator of inflammation to modulator of cardioprotection. Inflammopharmacol 12, 591–596 (2005). https://doi.org/10.1163/156856005774382760
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1163/156856005774382760